Aktienanalyse zu OptimizeRx Corp (OPRX)OPRXOptimizeRx Corp

OptimizeRx Corporation is a healthcare technology company. The Company’s platform combines artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. Its DAAP generates dynamic audiences with predictive analytics via machine learning methods. MNT creates consumer audiences using a privacy-first process. Its principal solutions include Audience Development: DAAP and MNT, Audience Profiling: Profiler, Audience Activation and Media Execution, Pharmacy Alerts, and Financial Messaging. Its Financial Messaging provides prescribers visibility to branded copay offers for patients directly within their electronic health record (EHR) systems and electronic prescribing (ERx) platforms. Its platform consists of a unified data intelligence technology stack, multiple cloud-based data warehouses, and in-house applications and application programming interface layers. It operates in the Technology sector (SERVICES-BUSINESS SERVICES, NEC industry).

OptimizeRx Corp (OPRX) appears to be a good buy right now, trading at $7.95 with a forward P/E of 7.97, indicating it may be undervalued compared to its earnings potential. Additionally, the company has shown a significant gross margin improvement, reaching 71.32% in Q2 2026, which supports profitability despite recent revenue challenges. The main risk is the revenue decline of 30% year-over-year reported in Q2 2026, which could impact future performance.

1 analysts cover OPRX: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 24.33.